Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3415-5
Abstract: Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense. Continuous daily dosing is available, but the acceptable dose and duration of therapy is… read more here.
Keywords: mgmt promotor; methylation negative; long term; promotor methylation ... See more keywords
Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-021-03912-6
Abstract: The cIMPACT-NOW update 6 first introduced glioblastoma diagnosis based on the combination of IDH-wildtype (IDHwt) status and TERT promotor mutation (pTERTmut). In glioblastoma as defined by histopathology according to the WHO 2016 classification, MGMT promotor… read more here.
Keywords: glioblastoma; histopathology; mgmt promotor; cpg sites ... See more keywords